Nutlin-3

製品コードS1061

Nutlin-3化学構造

分子量(MW):581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

サイズ 価格(税別)  
JPY 30710.00
JPY 18260.00
JPY 28220.00
JPY 61420.00
JPY 161020.00

カスタマーフィードバック(4)

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明 Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
ターゲット
Mdm2 [5]
(Cell-free assay)
180 nM
体外試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NXf5W49rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUe1xsDPxE1? MnnoOFjDqGh? M13iR4Jtd2OtczCyO{1QUENvaX7keYNm\CClZXzsJJBzd2yrZnXyZZRqd25iY3;tdIFz[WKuZTD0c{B1cGG2IH;mJIJie2GuIHzleoVtew>? M1y0cFI3OzVyNU[1
NP69 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PnbmlEPTB;M{GuOlnDuTJwNUSg{txO NWXYb5h5OjZ{NUK1O|U>
NP460 NE\PZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DiUGlEPTB;MkKuPFXDuTFwMUig{txO M{DuWFI3OjV{NUe1
C666-1 NYP4fppFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHwTWM2OD1zOT65OeKyQC57MzFOwG0> NVvPS2FTOjZ{NUK1O|U>
C666-1 NUTF[IhiS2WubDDWbYFjcWyrdImgRZN{[Xl? MVGxNEDDvU1? MUi0PEBp M1;DfGROW09? M1:zR5NmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJJRp\SCleYTveI95cWNiZX\m[YN1KG:oIHPpd5Bt[XSrbh?= NVraSoR6OjZ{NUK1O|U>
C666-1  NWq4fpZJTnWwY4Tpc44hSXO|YYm= MmLZNVAhyrWP M1TQZ|I1KGh? M4L6cmROW09? MkXrZYN1cX[jdHXzJJRp\SCyNUOgdIF1cHejeTygeZBz\We3bHH0bY5oKHB3MzygdFIyKGGwZDDN[I0z MYmyOlI2OjV5NR?=
C666-1 NWjoNZo3SXCxcITvd4l{KEG|c3H5 MlrQNVAhyrWP Mo\vOFgwPzJiaB?= MVrEUXNQ MYTz[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzDjbZNxdGG2aX6tbY5lfWOnZDDhdI9xfG:|aYO= NGHifYgzPjJ3MkW3OS=>
A549 MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLQNlQhcA>? M2nTWGlEPTB;MUeuOlghyrFiND61NkDPxE1? Mki1NlYyOjV{M{C=
A549-NTC NIPsdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjSWG1nOjRiaB?= MUDJR|UxRTF7LkSyJOKyKDFwOU[g{txO MoPqNlYyOjV{M{C=
A549-920 M4PXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuyOEBp NIHwZo1KSzVyPUOzMlg2KMLzIESuPFQh|ryP NFL5fHgzPjF{NUKzNC=>
CRL-5908 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLNW4wzPCCq Mn;hTWM2OD1|OD63NUDDuSB{LkSzJO69VQ>? NF;NU|YzPjF{NUKzNC=>
L6 NWXkRoh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfSVWwyOMLizszNxsA> MViyOE81QC95MjDo M3rYe2ROW09? MmDPbY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v NXzSTIllOjV6N{G3PVQ>
C2C12 M2rPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXziUHQ6OTEEoN88UeKh NYrselBVOjRxNEivO|IhcA>? NXPWTYFUTE2VTx?= NG[2SFdqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? M4rw[lI2QDdzN{m0
MCF-7  MWrGeY5kfGmxbjDBd5NigQ>? NVTwR286OTEEoN88US=> M1myN2ROW09? MYHpcohq[mm2czDjfYNtcW5iREGgZY5lKESrY3XyxsA> MYKyOVcxOjdyMx?=
DU4475  NXfq[5M3TnWwY4Tpc44hSXO|YYm= MXW1M|ExNzJyIN88US=> MVeyOOKhcA>? NHLofHpld3ewcnXneYxifGW|IGTvZ4EuOSCmb4PlJIRmeGWwZHXueIx6 NUHzPZJQOjV3NEexO|Q>
SMMC-7721 NIXsN21HfW6ldHnvckBCe3OjeR?= MXmxNEDPxE1? NYXxXZlkPDhiaB?= NVHvfYI{TE2VTx?= MmD6Z4F2e2W|IFTORUBFW0JiZHHtZYdm M{W3UFI2PTR2M{[x
SMMC-7721 MnHwSpVv[3Srb36gRZN{[Xl? M{DqflExKM7:TR?= NUXqUGF[PDhiaB?= MWTEUXNQ M2K2eIlv\HWlZYOgeIhmKGOqcn;tZZRqdi2kb4Xu[EBxem:2ZXnuJGlHUTF4IITvJJBienSrYXzsfUBtd2OjbHn6[UBqdiC2aHWgZ5l1d3CuYYPtxsA> MXqyOVU1PDN4MR?=
SMMC-7721 MlPaSpVv[3Srb36gRZN{[Xl? NVTQUZBpOTBizszN M1TZSFQ5KGh? NXLSe3J6TE2VTx?= Mmf5bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:owrDJSm5DOcLibWLORS=> MV[yOVU1PDN4MR?=
SMMC-7721 MlLCSpVv[3Srb36gRZN{[Xl? MVOxNEDPxE1? NYnBT2JyOzZiaB?= NYPIWIF2TE2VTx?= MkDpZ4F2e2W|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY> NVnNO3JFOjV3NESzOlE>
MCF-7 NGXLc45HfW6ldHnvckBCe3OjeR?= M{\ST|ExyqEQvF2= NHfwPWgxNTJ2IHi= NU\YT2Y2cW6mdXPld{BxPTNiYX7kJJAzOS:FaYCx MXmyOVQ5OjN5Mx?=
OVCAR10 M1LoSGZ2dmO2aX;uJGF{e2G7 Mnf4NVDDqM7:TR?= MVeyNYjDqA>? MlTpSG1UVw>? NGKzXZRqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ MWWyOVQzPjV2OB?=
NCI-H23 NIS5eWZHfW6ldHnvckBCe3OjeR?= M3:0XVExyqEQvF2= M{XrRVIycMLi MYLEUXNQ M2ew[Ilv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> MUiyOVQzPjV2OB?=
A2780 NVfrO|c3TnWwY4Tpc44hSXO|YYm= NV3FdGZCOTEEoN88US=> M{fYdVIycMLi NWqyPGw1TE2VTx?= MXLpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz NF7GVlczPTR{NkW0PC=>
NCI-H23 M3PhdmZ2dmO2aX;uJGF{e2G7 M3vQT|ExyqEQvF2= NXf6c3BPOjGqwrC= NUHEdo1HTE2VTx?= M1HuNYRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz MWSyOVQzPjV2OB?=
A2780 MkPISpVv[3Srb36gRZN{[Xl? MnG0NVDDqM7:TR?= M4[1WFIycMLi NWnlNVVVTE2VTx?= M2D3R4Rm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz M2nU[VI2PDJ4NUS4
HCT116  MkXoSpVv[3Srb36gRZN{[Xl? MWGxNEDDvU1? MUiyOEBp NWXMdWMy[2G3c3XzJIEheDV|LXTldIVv\GWwdDD0[ZRz[XCub3nkJGcyNWG{cnXzeEBqdiCmaYDsc4llKEiFVEGxOkBkdG:wZYOgSFMh[W6mIFS4 NW\ze29wOjV|OECwOVU>
MCF-10CA1a Mn7kSpVv[3Srb36gRZN{[Xl? NGTPV3AyOMLizszN M4fYcVQ5KGh? MmHVSG1UVw>? NIHiOGFqdmirYnn0d{Bj[XOjbDDpcpZie2mxbjDhcoQhemWmdXPl[EBVT0ZvzsKzMYlv\HWlZXSgbY53[XOrb36geI8h[mG|YXygcIV3\Wy| NWDoRpBmOjV{NUe3Nlk>
MCF-10A1  NH[yXlZHfW6ldHnvckBCe3OjeR?= M1Had|ExyqEQvF2= MUeyOE81QCCq NYfzOFNRTE2VTx?= NYSzN4IxcW6qaXLpeJMhdWmpcnH0bY9vKG:oIH7vdo1idCCkcnXhd5Qh\XCrdHjlcIlidMLi NVTJUpM{OjV{NUe3Nlk>
MCF-10CA1a NVfKNZlNTnWwY4Tpc44hSXO|YYm= NUPIT|Y1OTEEoN88US=> NIHURnMzPCCq NWj3W2MxTE2VTx?= NGjaeVZl\WO{ZXHz[ZMhfGinIGTHSk3PujNvaX7keYNm\CCvUl7BJIxmfmWuczDv[m1OWDJuwrDNUXA6NCCjbnVCpIlvfGWpcnnuxsDPusLiMx?= M3TSflI2OjV5N{K5
MCF-10CA1a NXi1RlJlTnWwY4Tpc44hSXO|YYm= MYqxNOKh|ryP Ml3DNlQhcA>? MYXEUXNQ MYTpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? M4WzPVI2OjV5N{K5
SK-BR-7 NXfzfnRITnWwY4Tpc44hSXO|YYm= NXvlW2Z2OTEEoN88US=> M2qzd|I1KGh? MXvEUXNQ M1\ld4lvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= M4fVc|I2OjV5N{K5
SUM102PT NIf2eI9HfW6ldHnvckBCe3OjeR?= NVvBU2VWOTEEoN88US=> MXiyOEBp M4nLTmROW09? MoLEbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NGPRPVIzPTJ3N{eyPS=>
RAW 264.7 MV\GeY5kfGmxbjDBd5NigQ>? NVfmV4xvOTEEoN88US=> MljpN|AhdWmw M2nJ[5Bz\X[nboTzJJRp\SCyNUOgdoVlfWO2aX;uJIlvKHKnc4DvcpNmKHSxIFzQVy=> NYPWW5g3OjVzN{K1OFc>
RAW 264.7 M{TjVGZ2dmO2aX;uJGF{e2G7 Ml7qNVDDqM7:TR?= NYfSbmRJOzBibXnu MVTy[YR2[2W|IITo[UBNWFNvYYXncYVvfGWmIITo[UBPTi4QulKgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHjeIl3cXS7 NXzKeWNpOjVzN{K1OFc>
RAW 264.7 NUXmZZpKTnWwY4Tpc44hSXO|YYm= NV\m[lY6OTEEoN88US=> MojEN|AhdWmw NF\DWY9qdmirYnn0d{BNWFNvaX7keYNm\CCQTzDwdo9lfWO2aX;uxsA> NHe2ZpgzPTF5MkW0Oy=>
MCF7  NWnlOWd1S2WubDDWbYFjcWyrdImgRZN{[Xl? MYCyMlUhyrWP NXPhVo5jPSCm NHTpUodFVVOR NYLONWpbe2Wwc3n0bZpmeyCPQ1[3JJRwKFCDUmCgbY5pcWKrdHnvci=> NYKzeW4yOjVyOEW5NFI>
MCF7  NFe2RphHfW6ldHnvckBCe3OjeR?= MojpNk42KML3TR?= NXTkTJdyPDhiaB?= Ml;rSG1UVw>? NHjOe|Vl\WO{ZXHz[ZMhfGinIHjvcY9td2exdYOgSHNDKHKncHHpdkBnemWzdXXuZ4lmew>? NXHOdHFlOjVyOEW5NFI>
ACHN MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYXxUJE5OC53LUGwJO69VQ>? M4\UUFAuPiCm Ml7BSG1UVw>? MXnpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVfndppwOjVyNke3PFc>
Caki-2 M1P2T2NmdGxiVnnhZoltcXS7IFHzd4F6 Mn3XNE42NTFyIN88US=> MUOwMVYh\A>? NI\EWm5FVVOR MnLkbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MmWyNlUxPjd5OEe=
A498 MoX1R4VtdCCYaXHibYxqfHliQYPzZZk> M{jLV|AvPS1zMDFOwG0> Moj4NE03KGR? MUjEUXNQ NXXDeIxHcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NULMU|RLOjVyNke3PFc>
115 MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3TWb|AvPS1zMDFOwG0> MlHiNE03KGR? NFO1WIpFVVOR MUnpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYiyOVA3Pzd6Nx?=
117 NEm2fpRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NILmbYsxNjVvMUCg{txO NFXmOZgxNTZiZB?= MoTPSG1UVw>? MXzpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MX6yOVA3Pzd6Nx?=
ACHN MULGeY5kfGmxbjDBd5NigQ>? NEPsSGkxNjVxMT:1JO69VQ>? MofQOFghcA>? MVvEUXNQ NXq1SYIydGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= M2Pl[VI2ODZ5N{i3
Caki-2 M3\wfWZ2dmO2aX;uJGF{e2G7 NEXwWlAxNjVxMT:1JO69VQ>? MXq0PEBp M{fo[mROW09? MYjs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? NITNflEzPTB4N{e4Oy=>
A498 M4\5ZWZ2dmO2aX;uJGF{e2G7 MUmwMlUwOS93IN88US=> MXe0PEBp NHWzboNFVVOR MVfs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? Mn3jNlUxPjd5OEe=
115 NFjWbXVHfW6ldHnvckBCe3OjeR?= MVKwMlUwOS93IN88US=> NYfZU5czPDhiaB?= MYPEUXNQ MVvs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MlXWNlUxPjd5OEe=
ACHN MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HJ[VUh|ryP M4PVTlQ5KGh? MmHWSG1UVw>? NFLae3lqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> MWSyOVA3Pzd6Nx?=
Caki-2 NH:ySmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:1JO69VQ>? M3nZVVQ5KGh? NITiO2xFVVOR NXj6XoVScW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh NWr3XohZOjVyNke3PFc>
A498 M1nK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rPcVUh|ryP NHvRfnQ1QCCq MYLEUXNQ MXHpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NYPJXXcxOjVyNke3PFc>
115 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LRRVUh|ryP NYnkZYdYPDhiaB?= M3TWOGROW09? NEK4[IlqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> M4q5Z|I2ODZ5N{i3
ACHN NV7COm5[TnWwY4Tpc44hSXO|YYm= NGTSeWg2KM7:TR?= NVm0[o11PDhiaB?= NG\kdZFFVVOR MXzpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi M3fLWVI2ODZ5N{i3
Caki-2 NULaV|hQTnWwY4Tpc44hSXO|YYm= NVLoc|ZjPSEQvF2= M1vC[VQ5KGh? M2\YOGROW09? M4\jU4lv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= MkP5NlUxPjd5OEe=
A498 M{jEW2Z2dmO2aX;uJGF{e2G7 MkLyOUDPxE1? NVe2TVlkPDhiaB?= MYjEUXNQ NWjhXm4zcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> M{LFSlI2ODZ5N{i3
115 M{\meGZ2dmO2aX;uJGF{e2G7 Mnz6OUDPxE1? Mkf0OFghcA>? NHrwb3VFVVOR M4K0Wolv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NVfMNItzOjVyNke3PFc>
MOLM-13 NIDsbnJHfW6ldHnvckBCe3OjeR?= NIjJ[Yo3yqEQvF2= NV3kVHRoOC16IHi= MVPEUXNQ M{Tvdolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIC1N{whVUSPMjygdFIyKGGwZDDhZ4V1gWyjdHXkJJA2Ow>? NUnuS4lCOjR6OEWwPFI>
MOLM-13 M2DjZmZ2dmO2aX;uJGF{e2G7 M4K4WlbDqM7:TR?= MUO2JIg> NVfyfm1ITE2VTx?= MUPlcohidmOnczD0bIUh[WOndInsZZRqd25ib3[gbIl{fG:wZTDINmIh[W6mIHjlZZQhe2ixY3ugdJJwfGWrboOgTJNxOjdiYX7kJGh{eDly NXn2[|d5OjR6OEWwPFI>
HepG2 NF3jVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GwfVczKGh? NY\OS5lPTE2VTx?= Mm\iTWM2OD1|NT64OkDDuSB{Lkmg{txO M4\MdFI1QDh2OEC5
HepG2/As M2XaSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPNUXc4OiCq MUHEUXNQ MWDJR|UxRTZ6LkGzJOKyKDlwNjFOwG0> NIHQUnYzPDh6NEiwPS=>
SMMC7721 M3X0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\OO|IhcA>? NUnyT2FpTE2VTx?= M4f1NGlEPTB;M{GuNlghyrFiND6yJO69VQ>? M4juZ|I1QDh2OEC5
SMMC7721/Ac NWXudFQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j6SlczKGh? M4S4NGROW09? NYL2bJpYUUN3ME21OU4zOSEEsTC1MlA{KM7:TR?= MkjCNlQ5QDR6MEm=
Huh-7 NIXEdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHoT5M4OiCq MUXEUXNQ M1[5XGlEPTB;M{OuPVYhyrFiMz65JO69VQ>? M1jjXFI1QDh2OEC5
Hep3B NUfsZ4hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYm3NkBp MW\EUXNQ MnXSTWM2OD1{MD6xPEDDuSBzLki0JO69VQ>? M330XlI1QDh2OEC5
HepG2 NIjmc2dCeG:ydH;zbZMhSXO|YYm= NESzN41qdmS3Y3XzJIFxd3C2b4Ppdy=> M{DHTlI1QDh2OEC5
SMMC7721 NFTGbYlCeG:ydH;zbZMhSXO|YYm= MlLBbY5lfWOnczDhdI9xfG:|aYO= M3rvUlI1QDh2OEC5
Huh-7 NGK1PINCeG:ydH;zbZMhSXO|YYm= MYXpcoR2[2W|IHHwc5B1d3Orcx?= NXnwO2pNOjR6OES4NFk>
Hep3B MmTqRZBweHSxc3nzJGF{e2G7 MlPhbY5lfWOnczDhdI9xfG:|aYO= NVTrR41SOjR6OES4NFk>
U2OS  M3zB[WZ2dmO2aX;uJGF{e2G7 NYPZZWY5OjBizszN NVzXdphKOjRiaB?= M3nVTolv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEKFTELBNUwhSkOOWF|CpIFv\EKFTGe= NYHqXpRQOjR6NkeyOVk>
AML2 MYLBdI9xfG:|aYOgRZN{[Xl? MkDUNk8yOCEQvF2= M2fWOVI1NzR6IHi= Ml\obY5lfWOnczDhdI9xfG:|aYO= NFfRSpgzPDZ3OUe0PS=>
MOML13 NYHoS5RESXCxcITvd4l{KEG|c3H5 MWmyM|ExKM7:TR?= M1v2XVI1NzR6IHi= MljjbY5lfWOnczDhdI9xfG:|aYO= NHT3elQzPDZ3OUe0PS=>
AML2 NFu2cYlHfW6ldHnvckBCe3OjeR?= MnPkNVDPxE1? Mn\PNk81KGh? M1vqc4lv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz M{jGelI1PjV7N{S5
AML3 MnjaSpVv[3Srb36gRZN{[Xl? M2e4[VEx|ryP MYCyM|QhcA>? M{D4UIlv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz NViyVlVNOjR4NUm3OFk>
MOML13 M1r0cGZ2dmO2aX;uJGF{e2G7 NYW4SXhwOTEQvF2= NUfTW4VQOi92IHi= NH33eJlqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> NWC4V5pWOjR4NUm3OFk>
BeWo MX\GeY5kfGmxbjDBd5NigQ>? M{PXXlMxKML3TR?= M{DUWFI1KGh? NHTCNXlqdmO{ZXHz[ZMheDV|LDDN[I0zNCCyMkGgZY5lKFC3bXGgZZQhfGinIIDyc5RmcW5ibHX2[Yw> NYPnfYNHOjR2OUixOVQ>
BeWo MmHwRZBweHSxc3nzJGF{e2G7 MYSzNEDDvU1? NYLLd4psOjRiaB?= MXnpcoNz\WG|ZYOgZZBweHSxc3nz M4jmdlI1PDl6MUW0
OCI NYfQUo5jTnWwY4Tpc44hSXO|YYm= NYOwdo5iOTBizszN MUOyOEBp Mn[2eZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w MVOyOFQ4OzV4Mh?=
MOLM NIjqeFRHfW6ldHnvckBCe3OjeR?= M4ezUVExKM7:TR?= MlWwNlQhcA>? M3Lu[5VxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= NYnVbIZMOjR2N{O1OlI>
U2OS  NXvCfIppTnWwY4Tpc44hSXO|YYm= NHXIU2gzOCEQvF2= MXuyOEBp Mmn1bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJGhQNTFicILveIVqdiCjczD3[YxtKGG|IITo[UBxPTNicILveIVqdg>? NFGxTW4zPDN4NkCwOy=>
RKO MoO4SpVv[3Srb36gRZN{[Xl? MUWyNEDPxE1? NYDXT2pWOjRiaB?= NFr3UZJqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw MWCyOFM3PjByNx?=
U2OS  M{PC[GZ2dmO2aX;uJGF{e2G7 MonkNlAh|ryP MXOyOEBp M4flPYlv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;u NXP0VIpCOjR|Nk[wNFc>
RKO MX7GeY5kfGmxbjDBd5NigQ>? NH\0SWEzOCEQvF2= MX2yOEBp NH3ZfJBqdmS3Y3XzJGhQNTFiZYjwdoV{e2mxbjDheEB1cGVibHX2[Ywhd2ZidILhcpNkemmydHnvci=> MoDvNlQ{PjZyMEe=
SMMC-7721  Ml\BR4VtdCCYaXHibYxqfHliQYPzZZk> MUWxMlI2NTJyIN88US=> NXfyd5BKOjRxNEivO|IhcA>? Mmr6SG1UVw>? M4HKPIlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 MVGyOFI5PjNzMh?=
HuH-7 M1HXWmNmdGxiVnnhZoltcXS7IFHzd4F6 Mni5NU4zPS1{MDFOwG0> NHfqWoczPC92OD:3NkBp NVzV[XFKTE2VTx?= NHjYSnhqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> NUD1ZnRkOjR{OE[zNVI>
SMMC-7721  MV\BdI9xfG:|aYOgRZN{[Xl? MXWyNEDPxE1? NHT4Noc1QCCq NUG1R4M4TE2VTx?= NXHZWHpzcW6mdXPld{BieG:ydH;zbZM> NFzWfGszPDJ6NkOxNi=>
HuH-7 M3;wcWFxd3C2b4Ppd{BCe3OjeR?= M1S5N|IxKM7:TR?= MYK0PEBp MUXEUXNQ NGCze5FqdmS3Y3XzJIFxd3C2b4Ppdy=> MmjMNlQzQDZ|MUK=
SMMC-7721  M2rufWZ2dmO2aX;uJGF{e2G7 MW[xNEDPxE1? NGewNZE{PiCq NVXrT|lHTE2VTx?= MVHkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> NUXsfZBbOjR{OE[zNVI>
HuH-7 NFSw[JdHfW6ldHnvckBCe3OjeR?= NWWzWHdGOTBizszN M33odVM3KGh? M3XHOGROW09? MVfkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> MoLBNlQzQDZ|MUK=
AT2 NEPR[I9HfW6ldHnvckBCe3OjeR?= NGn5PVM2NzFyIN88US=> MV\s[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? NF\GW2YzPDJ2MEKwNy=>
REH NVHn[4Z{TnWwY4Tpc44hSXO|YYm= Ml75OU8yOCEQvF2= M1nvNoxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li NH;oOnQzPDJ2MEKwNy=>
UoCB6 MU\GeY5kfGmxbjDBd5NigQ>? MWO1M|ExKM7:TR?= MoXCcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? NIPpVmYzPDJ2MEKwNy=>
AT2 NVvrPXFoS2WubDDWbYFjcWyrdImgRZN{[Xl? NGrYWVkxNTJ3IN88US=> NXPUXVQzcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M4jlSFI1OjRyMkCz
REH M4nWRmNmdGxiVnnhZoltcXS7IFHzd4F6 NX;kRYRxOC1{NTFOwG0> MYLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NV\WWmsxOjR{NECyNFM>
UoCB6 MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUfKNmR[OC1{NTFOwG0> NI\zU3VqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NGPBc20zPDJ2MEKwNy=>
A2780 NV;uS2JCTnWwY4Tpc44hSXO|YYm= MlPrOU8yOC9{MDFOwG0> NGrzWJUzPCCq MoPreZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? NWrUPVNyOjRzM{[xOFc>
H460 MUjGeY5kfGmxbjDBd5NigQ>? MlP0OU8yOC9{MDFOwG0> MYCyOEBp M1:weZVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi MX:yOFE{PjF2Nx?=
Lovo  NIPHdWxHfW6ldHnvckBCe3OjeR?= MUe1M|ExNzJyIN88US=> NV;H[oNSOjRiaB?= MWT1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? Mm\CNlQyOzZzNEe=
A2780 NFPPNGFCeG:ydH;zbZMhSXO|YYm= MVW1M|ExNzJyIN88US=> M1LK[lI1KGh? Ml:z[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> NXTicHdqOjRzM{[xOFc>
H460 NVK3fGpzSXCxcITvd4l{KEG|c3H5 Ml7FOU8yOC9{MDFOwG0> NIHPbJczPCCq NVHaWIVE\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? NVKyWlNQOjRzM{[xOFc>
Lovo  MlnIRZBweHSxc3nzJGF{e2G7 MXu1M|ExNzJyIN88US=> M{nvc|I1KGh? NXrwNJBZ\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? NYToUoh2OjRzM{[xOFc>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞試験:

[1]

+ 展開
  • 細胞株: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • 濃度: Dissolved in DMSO, final concentrations ~ 30 μM
  • 反応時間: 8, 24, and 48 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • 製剤: Formulated in 2% Klucel, 0.5% Tween 80
  • 投薬量: 200 mg/kg
  • 投与方法: Orally, twice a day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 581.5
化学式

C30H30Cl2N4O4

CAS No. 890090-75-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答:

    It is a racemate.

Mdm2シグナル伝達経路

相関Mdm2製品

Tags: Nutlin-3を買う | Nutlin-3 ic50 | Nutlin-3供給者 | Nutlin-3を購入する | Nutlin-3費用 | Nutlin-3生産者 | オーダーNutlin-3 | Nutlin-3化学構造 | Nutlin-3分子量 | Nutlin-3代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID